BackZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) Overview
ZyVersa Therapeutics Inc - Units (1 Ord Share Class A & 3/4 War)

ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) Return on Equity

Latest ROE for ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War): 173.38% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

ROE

173.38%

Return on Equity

173.38%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

Average ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) (LSPRU) FAQ

ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War)'s return on equity stands at 173.38%. That is above the sector sector average of -4.47%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) sits higher the its sector benchmark (-4.47%) with a ROE of 173.38%. That is roughly 3980.2% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A ROE of 173.38% for ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War)'s ROE evolved across reporting periods, while the comparison chart places LSPRU next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.